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Abstract
Background: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to
patients when no other drug product is available for a rare disease or during periods of drug product shortages.
Additionally, it allows customized therapy for patients with rare diseases. However, standardized compounding
formulas and procedures, and monographs are required to ensure the patients’ safety.
Results: Standardized formulas and compounding procedures were developed for seven orphan active ingredients
(L-arginine, sodium benzoate, sodium phenylbutyrate, L-carnitine, chenodesoxycholic acid, primaquine phosphate,
pyridoxal phosphate) and one non-orphan molecule (sodium perchlorate) regularly compounded by hospital
pharmacists for extemporaneous use. The stability of these formulations was evaluated over 3 months at refrigerated
(5 °C) and standard storage conditions (25 °C/60%RH) using HPLC-based assays and a suitable shelf life was assigned to
the formulations. Additionally, suitable analytical methods for quality control of formulations of pyridoxal phosphate
and sodium perchlorate were developed as monographs for these components were not available in the European
Pharmacopeia or United States Pharmacopeia.
Conclusions: Availability of compounding formulas and protocols, as well as stability information, for orphan active
ingredients can improve patients’ access to treatment for rare diseases. Such data were collected for seven orphan
active ingredients to treat patients with rare diseases when no other treatment is available. More efforts are needed
to develop standardized formulas and compounding procedures for additional orphan active ingredients whose
clinical efficacy is well-known but which are not available as products with a marketing authorization. Additionally,
a legal framework at EU level is required to enable the full potential of pharmaceutical compounding for orphan
active ingredients.
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Background
In the European Union (EU), rare diseases are defined as
life-threatening or chronically debilitating conditions
that affect no more than five in 10 000 patients [1]. It is
estimated that 5000 to 8000 rare diseases exist world-
wide, while approximately 250 new diseases are de-
scribed annually [1–3]. Although their prevalence is low,
rare diseases affect 27 to 36 million people in the EU
[1, 2]. Orphan medicinal products (OMPs) are defined by
the EU as drug products intended for a condition for
which there exists no authorized satisfactory method of
diagnosis, prevention or treatment or, if so, that it will be
of significant benefit to those affected by the condition [1].
The development of and patient access to OMPs is there-
fore an important challenge for public health policy-
makers. However, the challenges associated with OMPs
are manifold and are mainly related to lack of research
and development of OMPs and patient access to OMPs.
The low number of patients with a particular rare dis-
ease can limit OMP development due to the risk for
pharmaceutical companies to achieve sufficient return
on their investment and the difficulty in recruiting suffi-
cient numbers of patients to prove statistically significant
effects in clinical trials [3]. The economical aspect was
addressed by the Orphan Drug Act in the United States
in 1983 and the adoption of the European Commission
Regulation Number 141/2000 and 847/2000 in 2000, of-
fering economic and regulatory incentives [3]. In the EU,
these include protocol assistance, 10-year market exclu-
sivity and fee waivers for regulatory procedures for des-
ignated products for companies investing in the research
and development of OMPs [3]. Additionally, the US
Food and Drug Administration (FDA) and the European
Medicine Agency (EMA) have enabled a common EMA-
FDA application for orphan designation. Next to OMP
development, patient access is essential but is often
limited by high costs and lack of reimbursement [4]. As
pricing and reimbursement of OMPs are EU member
state responsibilities, patient access varies within the EU.
The EU Commission therefore set up a working party to
exchange knowledge between member states on scien-
tific assessment of the clinical added value of orphan
medicines that can facilitate national pricing and reim-
bursement decisions [5].
An increasing number of OMP designations and
authorizations have been reported in the EU since 2000
[3, 6]. From 2000 to 2017 the EMA reported 1952 active
OMP designations (i.e. designation of the status of OMP
to a drug product) while 142 products received market
authorization (i.e. a license to market a drug product)
[6]. This is a success considering that there was almost
no development of OMPs in the EU prior to 2000 [3, 6].
However, this also signifies that for less than 2% of rare
diseases, authorized medicinal products are available in
the EU and that continued efforts from the EU and its
member states are required [2]. Therefore, the EU
Commission and Council obligated their member states
to develop dedicated national strategies to pursue a
comprehensive and integrated approach to the delivery
of health and social care for rare disease patients [1, 5].
In Belgium, the Fund for Rare Diseases and Orphan
Drugs drafted a report including 42 recommendations
and proposals for a national plan for rare diseases [7].
These recommendations are related to (1) expertise and
multi-disciplinarity, (2) collaboration and networking,
(3) knowledge, information and awareness, (4) equity in
access, (5) governance and sustainability [7]. A measure
to improve equity in access comprises creation of a legal
framework to use orphan active ingredients (OAIs) in
compounded preparations. Simultaneously, compound-
ing of OAIs could offer opportunities to cut costs in the
health care budget. Based on the latest available figures,
the Belgian social security services reimbursed an in-
creasing number of OMPs from 2009 to 2016, with ex-
penditures rising from around 150 million euro in 2009
up to more than 350 million euro in 2016, which ac-
counts for a rise from around 4% to up to more than 8%
of the budget spent on medicine reimbursement [8].
Begin 2018, 149 OMPs had a marketing authorization
and 61% of these were reimbursed [8]. Some OMPs were
not reimbursed because alternatives exist that are more
cost-effective or due to budgetary restrictions, while for
others no reimbursement was applied for or the applica-
tion procedure is still ongoing [8].
Some well-known OAIs for treatment of orphan dis-
eases are not available to patients as products with a
marketing authorization. Consequently, off-label use is
widespread for treatment of orphan diseases [9]. How-
ever, compounding of OAIs could address these patients’
needs. Additionally, compounding of OAIs can address
the needs of pediatric or geriatric patients, offering dos-
ing flexibility, and of patients with hypersensitivity, intol-
erances and allergies to specific excipients of authorized
drug products. However, three main obstacles must be
overcome to use OAIs in compounded preparations.
Firstly, compounding of OAIs should be performed by
pharmacists applying standardized compounding proce-
dures and formulas, with knowledge of the stability, in
order to assure patient safety [10]. Secondly, mono-
graphs for pharmaceutical analysis of OAIs are often not
available, hence suitable analytical methods must be
developed for quality control of these compounds,
reflected in their certificates of analysis, as well as for
the compounded formulations. Thirdly, there is a lack of
EU-uniform legal framework to use OAIs in com-
pounded preparations. Despite these hurdles, some OAIs
are currently used in enteral and parenteral preparations
compounded in community and hospital pharmacists in
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Belgium and other countries when no other treatment is
available for patients with rare diseases [11–14]. Never-
theless, to ensure the patients’ safety and to improve the
equity in access, efforts are needed to develop standard-
ized compounding procedures and formulas, to develop
quality monographs (if none are available) and to create
a legal framework.
The Laboratory of Drug Quality and Registration and
the Laboratory of Pharmaceutical Technology at Ghent
University took the initiative to develop formulas and
standard compounding procedures and to develop
suitable analytical methods for quality control of the
compounded formulations in order to promote pharma-
ceutical compounding of OAIs by hospital and commu-
nity pharmacists. These formulas and procedures are
outlined in the current paper.
Methods
Materials
An overview of the OAIs, excipients and packaging used
in the formulations is given in Table 1.
Methods
Selection of orphan active ingredients
A list of OAIs for use in galenic preparations and show-
ing an unmet medical need was composed by an expert
panel, consisting of 20 hospital pharmacists, and ap-
proved by the Belgian National Formulary commission.
These OAIs were scored based on (A) the prevalence of
the corresponding rare disease, (B) severity of the dis-
ease, (C) degree of available clinical and therapeutical
evidence, (D) price of the OAI and (E) ease of compound-
ing. Scores from 1 (for questionable/low) to 3 (for
evident/high) were assigned to these criteria. Next, a
weighing factor was assigned to the criteria depending on
their importance (Table 2). Finally, the total score was calcu-
lated by summing the scores of the individual criteria multi-
plied with the corresponding weighing factor (Table 2). All
active ingredients included in current study obtained
orphan designation by EMA and/or FDA [15, 16].
Development of compounding formulations
The OAIs were compounded as liquid (solutions) or
solid (capsules) formulations intended for oral adminis-
tration. The choice for a specific dosage form depended
on the OAI dose, dosing frequency, patient population,
solubility and sensitivity to air, heat and light. The OAI
concentration in the liquid formulations and the OAI
content per capsule was based on scientific literature
and the expert panel’s advice (Table 3).
The preparation of the formulations was standardized
following the best practices described in the Belgian
National Formulary. Capsules were prepared using a man-
nitol/colloidal silicon dioxide mixture (99.5/0.5 w/w%) as
a non-hygroscopic, non-reducing filler. Capsule size num-
ber 2 or larger was used. Capsules were packaged in plas-
tic opaque cups of 100ml. Solutions were compounded by
Table 1 Overview of the OAIs, excipients and packaging used
in the compounded formulations
OAIs Supplier
L-arginine Fagron, Waregem, Belgium
L-carnitine Fagron, Waregem, Belgium
Chenodesoxycholic acid BOC Sciences Creative Dynamics,
Shirley, United States
Primaquine phosphate BOC Sciences Creative Dynamics,
Shirley, United States
Pyridoxal phosphate Inresa, Bartenheim, France
Sodium benzoate Fagron, Waregem, Belgium
Sodium perchloratea Merck, Darmstadt, Germany
Sodium phenylbutyrate Fyrklovern Scandinavia AB,
Mönsteras, Sweden
Excipients Supplier
Aurantii amari epicarp et
mesocarp tinctura
Conforma, Destelbergen, Belgium
Sirupus simplex Conforma, Destelbergen, Belgium
Methyl paraben Fagron, Waregem, Belgium
Propyl paraben Fagron, Waregem, Belgium
Mannitol Fagron, Waregem, Belgium
Colloidal silicon dioxide Fagron, Waregem, Belgium
Packaging Supplier
Hard gelatine capsules Capsugel, Bornem, Belgium
Glass bottles 100 ml Aca Pharma, Nazareth, Belgium
Plastic opaque cups Aca Pharma, Nazareth, Belgium
aSodium perchlorate is not an OAI but was included in the study as an
unlicensed molecule regularly compounded by hospital pharmacists for
extemporaneous use
Table 2 Priority list of the OAIs
A (2) B (4) C (3) D (2) E (1) total
Amifampridine 6 12 9 6 3 36
Sodium phenylbutyratea 6 12 9 2 3 32
Pyridoxal phosphatea 6 8 9 6 3 32
Chenodesoxycholic acida 2 12 9 6 3 30
Primaquine phosphatea 2 12 9 6 3 30
Fenfluramine 2 12 6 6 3 29
Sodium hydroxybutyrate 2 12 3 6 3 26
Difencyprone 6 4 6 6 3 25
Bimyconase 2 8 6 2 1 19
Priority list of the OAIs based on five criteria with (A) the prevalence of the
corresponding rare disease, (B) severity of the disease, (C) degree of available
evidence, (D) price of the orphan active ingredient and (E) the ease of
compounding. The weighing factor (which was multiplied with the score of
the individual criterium) indicating the criteriums importance is mentioned
between brackets. aOAIs included in current study
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Table 3 Overview of the OAIs included in current study
Orphan disease Prevalence (/100.000)
or number of
published cases [15]
Recommended dose Reference Developed dosage form
with OAI concentration
(solutions) or OAI mass per
dosage unit (capsules)
L-arginine, sodium
benzoate, sodium
phenylbutyrate
Hyperammonemia:
carbamoyl Phosphate
synthase deficiency
0.31P L-arginine: < 20 kg:
100–200mg/kg/day;
> 20 kg: 2.5–6 g/m2/day
(max. 6 g/day)
Sodium benzoate: up to
250mg/kg/day (max.
12 g/day)
Sodium phenylbutyrate:
< 20 kg: ≤ 250mg/kg/day;
> 20 kg: 5 g/m2/day
(maximum: 12 g/day)
[17] L-arginine: 10 g/100ml
solution
Sodium benzoate:
10 g/100 ml solution
Sodium phenylbutyrate:
20 g/100 ml solution
Hyperammonemia:
ornithine transcarbamylase
deficiency
1.4P*
Hyperammonemia:
citrillinaemia or
argininosuccinate synthase
deficiency
Hyperammonemia:
argininosuccinic aciduria or
argininosuccinate lyase
deficiency
2.4P*
1.0P*
L-arginine: < 20 kg:
100–300mg/kg/day; > 20 kg:
2.5–6 g/m2/day (max.
6 g/day)
Sodium benzoate: up to
250mg/kg/day (max.
12 g/day)
Sodium phenylbutyrate:
< 20 kg: ≤ 250mg/kg/day;
> 20 kg: 5 g/m2/day
(maximum: 12 g/day)
[17]
Hyperammonemia due to
N-acetylglutamate synthase
deficiency
12a L-arginine: < 20 kg:
100–200mg/kg/day;
> 20 kg: 2.5–6 g/m2/day
(max. 6 g/day)
Sodium benzoate: up to
250mg/kg/day (max.
12 g/day)
[17]
L-carnitine Carnitine palmitoyl
transferase1A deficiency
50 cases N.A. 20 g/100 ml solution
Carnitine-acylcarnitine
translocase deficiency
60 cases N.A.
Medium-Chain Acyl-
Coenzyme A
Dehydrogenase Deficiency
3.2 BPa 100 mg/kg/day [18]
Systemic primary carnitine
deficiency
6.85 P 100–400mg/kg/day [19]
Sodium Benzoate Non-ketotic hyperglycemia
Glycine encephalopathy
0.17 P* 250–750mg/kg/day [20] 10 g/100 ml solution
Chenodesoxycholic acid Cerebrotendinous
xanthomatosis
< 5 P 750mg/day [21, 22] 250 mg capsules
Primaquine phosphate Malaria 3.0 P* 500 μg/kg and 250 μg/kg
daily for 14 days
[23–26] 30 mg capsules
Pneumocystis carinii
pneumonia
N.A. 15 mg/day
Pyridoxal phosphate Pyridoxamine 5′-oxidase
deficiency
0.2 P* 30 – 50 mg/kg/day [27, 28] 10 mg capsules
Sodium perchloratea Prophylactic thyroid
protection during
radiological examination
using iodine contrast
agents
N.A. 1 g/day [29] 50 mg/ml solution
Overview of the OAIs included in current study, the corresponding orphan diseases, overall prevalence worldwide (P) or in Europe (P*), birth prevalence
worldwide (BP) or number of published cases, recommended dose and dose of compounded formulation (N.A.: data not available). aSodium perchlorate is not an
OAI but was included in the study as an unlicensed molecule regularly compounded by hospital pharmacists for extemporaneous use
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dissolving the AOI in a glass flask in 50ml demineralized
water containing 0.02% propylparahydroxybenzoate (PBA)
and 0.08% methylparahydroxybenzoate (MBA). Next, at
least 85 g sirupus simplex (consisting of 65.00 w/w%
sucrose, 0.02% propylparahydroxybenzoate and 0.08%
methylparahydroxybenzoate in deionized water) and 3 g
aurantii amari epicarp et mesocarp tincture were added.
Finally, the preparation was diluted with sirupus simplex
up to a total volume of 100ml. The solutions were filled
into transparent glass flasks, except for the L-arginine so-
lution which was filled into a brown glass flask to avoid
degradation through light exposure [30].
Stability testing
Identification, assay, related substances (i.e. degradation
products), mass uniformity (for capsules) and pH (for so-
lutions) tests were conducted on the preparations imme-
diately after preparation (T0), after 3months storage at
5 °C (T3_5°C), after 1 (T1_25°C/60%RH) and 3 (T3_25°C/
60%RH) months storage at 25 °C and 60% relative humid-
ity (RH) in constant climate chambers (Pharma 500 l,
Weiss Technik, Liedekerke, Belgium). For chenodesoxy-
cholic acid capsules, no data was collected after 3months
but after 4months storage. Maximal storage duration of 3
or 4months was considered sufficient, as the com-
pounded formulations are delivered to the patient imme-
diately after preparation. Due to detection of degradation
products in the arginine solutions, assay determination of
MBA and PBA in the arginine solutions was performed
after 1 and 2months storage under two conditions: (1) in
the fridge (5 °C) and (2) at 25 °C and 60% RH (no data was
collected after 3months storage as clear degradation of
the parabens was already detected after 2months).
Additionally, all samples were visually inspected at all
timepoints for color change and evaluated for odor.
All identification, assay and related substances (i.e. deg-
radation products) tests, except for chenodesoxycholic
acid and sodium perchlorate, were performed using in-
house developed and validated high-performance liquid
chromatography (HPLC) methods with ultraviolet (UV)
spectroscopy detection. Identification, assay and related
substances tests, of sodium perchlorate were performed
using an in-house developed and validated UPLC method
with mass spectrometry detection. The details of these
analytical methods are given in Table 4. Identification and
determination of the related substances, impurities and
degradation products of chenodesoxycholic acid was per-
formed by thin layer chromatography as described in its
European Pharmacopeia (Ph. Eur.) monograph whereas
assay of chenodesoxycholic acid itself was performed by
acid-base titration using an aqueous sodium hydroxide
solution [31].
An OAI was identified when its retention time was
within ±0.5 min of the retention time of the OAI peak in
a reference standard (the active ingredient used in the
formulation) or when the principal spot on the thin layer
chromatogram of the test solution was similar in
position, color and size to the principal spot in the
chromatogram obtained with the reference solution. For
assay determination via HPLC, two reference solutions
and two sample solutions were prepared independently
and analyzed in duplicate. Standard curves of each com-
ponent were constructed via linear regression of the
peak area to the concentration and used to calculate the
percentage label claim. The formulations complied to
the assay test when the assay of the solutions and cap-
sules was within a 90–110% label claim and 85–115%
label claim interval, respectively. A reporting threshold
of 0.1% label claim was applied for related substances
(i.e. degradation products) according to the Ph. Eur.
monograph on substances for pharmaceutical use, unless
other limits were included in the specific Ph Eur. mono-
graph of a OAI [32]. The mass uniformity of the cap-
sules was evaluated at release and during stability testing
according to the monograph for uniformity of mass of
single dose preparations of the Ph. Eur. [33].
Results
Selection of orphan active ingredients
A priority list based on the scores assigned to the
unlicensed OAIs defined by an expert panel of the Belgian
National Formulary is given in Table 2. It was decided to
develop standard compounding procedures for the OAIs
with the five highest scores. Although amifampridine
scored highest, no compounding procedure was devel-
oped as this is already available in the German National
Formulary (Deutsche Artsenei Codex). Standardized for-
mulas and compounding procedures were developed for
sodium phenylbutyrate, pyridoxal phosphate, chenode-
soxycholic acid and primaquine phosphate. Additionally,
standardized formulas and compounding procedures were
developed for three licensed OAIs which are frequently
compounded in Belgian hospital pharmacies but whose
stability was not investigated up to now: L-arginine,
L-carnitine and sodium benzoate. Sodium perchlorate,
which is not an OAI but an unlicensed molecule, was also
included in the study based on the input of the expert
panel as sodium perchlorate is frequently compounded by
hospital pharmacists for extemporaneous use prior and
after radiological examination of the thyroid, although
stability data was lacking up to now.
An overview of the compounded OAIs, their recom-
mended dose and the corresponding developed for-
mulation is presented in Table 3. Additionally, the rare
diseases and their prevalence for the corresponding
OAIs are included in Table 3.
Next to the standardized formulas and compounding
procedures, suitable analytical methods were developed
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for quality control of pyridoxal phosphate and sodium
perchlorate formulations as no monographs for these
components were available in the Ph. Eur. or USP. De-
tails of these tests are included in Table 4.
Stability testing
The suitability of the developed formulas and com-
pounding procedures was evaluated via stability testing
to investigate how long the extemporaneously produced
preparations can be stored and which storage conditions
should be applied to ensure their activity. All formula-
tions complied with the mass uniformity test, identifica-
tion and related substances tests at release. Additionally,
all formulations complied with the mass uniformity and
identification tests during stability testing. An overview
of the assay results at the investigated time points is pre-
sented in Table 5. The L-carnitine, sodium benzoate and
sodium phenylbutyrate solutions and chenodesoxycholic
acid, pyridoxal phosphate and primaquine phosphate
capsules were stable over 3 months under all storage
conditions. All formulations, except the L-carnitine and
L-arginine solutions, complied to the specifications for
related substances (i.e. degradation products). A degrad-
ation peak (RRT 0.89) exceeding the reporting threshold
(0.10% label claim) was detected in the L-carnitine solu-
tions after 1 (0.24% label claim) and 2months (0.17%
label claim) only (and not after 3 months). However, as
the assay of L-carnitine was stable over 3 months and as
the detected degradation peak was a broad HPLC-peak,
which is atypical for a well-identified degradant, it was
assumed that the observed degradation peak was due to
degradation of the aroma, aurantii amari epicarp et
mesocarp, which is a complex mixture [34, 35].
Therefore, a shelf life of 3 months was assigned to
the L-carnitine solutions. L-arginine was stable over the
tested time period, but degradation of PBA and MBA in
the L-arginine solution was observed after 1month stor-
age at both refrigerated and 25 °C/60% RH conditions in a
brown glass flask. Paraben degradation was attributed to
hydrolysis in alkaline environment, as paraben hydrolysis
is commonly observed at pH values exceeding 7.0, and as
the pH of the L-arginine solutions was 10.5. An overview
of the paraben decrease over time in function of the
storage conditions is given in Fig. 1. Faster degradation
Table 4 Overview of the applied analytical methods
Column HPLC Mobile phase Flow rate
(ml/min)
UV detection
wavelength (nm)
Column oven
temperature (°C)
Injection
volume (μl)
L-arginine Nucleodur NH2-RP, 5 μm,
4.6 mm × 150mm
Isocratic: phosphate
buffer pH 7.0/acetonitrile
47/53
0.8 210 30 20
L-carnitine Nucleodur NH2-RP, 5 μm,
4.6 mm × 150mm
Isocratic: phosphate
buffer pH 4.7/acetonitrile
40/60
0.8 205 30 20
Primaquine phosphate Symmetry C8, 3.5 μm,
3mm× 150mm
Isocratic: acetonitrile/
tetrahydrofuran/trifluoro
acetic acid/water
9/1/0.1/90
0.75 265 30 10
Pyridoxal phosphate Prevail C18, 5 μm,
4.6 mm × 250mm
Isocratic: 25 mM KH2PO4
pH 3/acetonitrile 97/3
1 212 25 20
Sodium benzoate Prevail Organic acid,
5 μm, 4.6 mm × 250mm
Isocratic: Water/
acetonitrile 75/25 + 0.1%
(m/V) formic acid
1.0 225 25 20
Sodium perchlorate Primesep D column,
5 μm, 3.2 mm × 150mm
equipped with suitable
guard column
Gradient with A: 10/90
acetonitrile/water (V/V) +
30 mM ammonium
formate, B: 40/60
acetonitrile/water + 80
mM ammonium formate
0.6 -a 30 1
Sodium phenylbutyrate C18, end-capped,
base-deactivated, 5 μm
Isocratic: glacial acetic
acid/methanol/water
1/49/50
1.1 245 35 20
MBA, PBA C18, 5 μm, 4.6 mm×
150mm
Gradient with A: 95/5
0.62% (m/V) KH2PO4 in
water/methanol (V/V), B:
5/95 0.62% (m/V) KH2PO4
in water/methanol (V/V)
1.2 245 25 10
Overview of the column type, mobile phase, flow rate, UV detection wavelength, column oven temperature and injection volume applied in the HPLC methods.
A gradient was used for analysis the sodium perchlorate formulation (0 min: 100% A, 0% B; 12 min: 0% A, 100% B, 12.5 min: 100% A, 0% B) and for assay of MBA,
PBA in the L-arginine formulation (0 min: 90% A, 10% B; 17 min: 36% A, 64% B; 22 min: 90% A, 10% B). aDetection of sodium perchlorate was performed by
mass spectrometry
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was observed for MBA compared to PBA which was at-
tributed to the stronger resistance to hydrolysis observed
with an increase in alkyl chain length of parabens [36]. As-
suming linear degradation kinetics, based on the collected
data points, the arginine solution could be stored for max-
imum 9 days under refrigerated conditions. Therefore a
shelf life of 1 week under refrigerated conditions was rec-
ommended (Table 5).
Discussion
The developed formulas and compounding procedures
for the selected OAIs can offer patient access to treat-
ment of rare diseases when no commercial orphan me-
dicinal product (OMP) is on the market, provided a
legal framework is created. Additionally, similar work
should be performed for other OAIs that are not com-
mercially available to address the needs of patients with
rare diseases. Several OAIs were suggested in the report
of the Belgian Fund for Rare Diseases and Orphan Drugs
or by the expert panel including d,I-3-sodiumhydroxybu-
tyrate, amiloride, bi-myconase, I-citrulline, CoEnzyme
Q10, diphencyprone, d-mannose, d-ribose, fenfluramine,
glycine, hydroxobalamine, oxybutinine, squaric acid dib-
uty ester, potassium citrate, propranolol and sodium
thiosulphate [7].
Next to increasing patient access, compounding of
OAIs can also be an interesting way to cut costs in the
portion of the health care budget dedicated to rare dis-
eases. Although some OMPs are novel or complex new
chemical entities developed at high research and devel-
opment (R&D) costs, such high R&D costs are not ap-
plicable to others as either evidence of their efficacy has
already been published in literature prior to market
authorization, or because the drug product was already
developed for another diseases, decreasing to some
extend the costs in the quality and preclinical field
[37, 38]. In this context, Simoens et al. compared the price
of commercially manufactured OMPs to compounding
Fig. 1 Label claim% of MBA and PBA in the L-arginine solution in function of time. Label claim % of MBA (grey) and PBA (black) included in the
L-arginine solution after storage at 5 °C (●) or 25 °C and 60%RH (■)
Table 5 Overview of the shelf life and assay stability results
Assay T0 T3_5°C T1_25°C/60%RH T3_25°C/60%RH Shelf life
L-arginine solution 98.7; 98.8 100.3; 99.9a 100.8; 99.9a 98.5; 97.4a 1 week refrigerated (5 °C)
L-carnitine solution 98.6; 100.8 102.7; 102.8 103.5; 102.9 99.3; 99.9 3 months
Chenodesoxycholic acid capsules 96.9; 96.3; 96.6 97.6; 97.6; 97.6 98.9; 99.4; 99.3 101.2; 100.4b 3 months
Primaquine phosphate capsules 105.7; 101.8 98.4; 99.7 95.3; 96.7 95.3; 99.7 3 months
Pyridoxal phosphate capsules 104.9; 104.6 105.5; 101.8 100.3; 100.3 101.2; 100.2 3 months
Sodium benzoate solution 99.0; 99.5 101.8; 101.6 100.2; 100.1 100.6; 97.2 3 months
Sodium perchlorate solution 90.4; 96.18 92.1; 90.1 90.6; 93.2 91.7; 89.12 3 months
Sodium phenylbutyrate solution 99.7; 99.5 99.4; 101.5 100.0; 100.9 96.7; 99.7 3 months
Overview of the shelf life and assay stability results (n = 2 or n = 3) immediately after production (T0), after 3 months refrigerated storage (T3_5°C), after 1
(T1_25°C/60%RH) and 3 (T3_25°C/60%RH) months storage at 25 °C and 60% RH. Formulations complied to the assay test when the assay of the solutions and
capsules was within a 90–110% label claim and 85–115% label claim interval, respectively. aDegradation products of PBA and MBA were detected, bStability data
was not collected after 3 months but after 4 months
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costs in a community pharmacy for a selection of orphan
drugs on the Belgian market in 2011. The price of com-
mercially manufactured OMPs exceeded 2- to 148-fold the
compounding costs for the studied OMP [38].
While standardized formulas and compounding proce-
dures were developed for seven OAIs in current study,
monographs and compounding procedures for other
OAIs are included in the German National Formulary
(e.g. cysteamine, polyhexamethylbiguanide, amifampri-
dine), USP (e.g. mepacrine) or others. Dooms et al. listed
national formularies and other reliable sources available
worldwide to retrieve information on compounding of
OAIs for rare diseases [10]. To realize all benefits of
compounding OAIs, it is essential to create a legal
framework for their use. Preferably, this should be orga-
nized at EU level by creation of an authority listing and
certifying OAIs and issuing a formulary including stan-
dardized formulas and compounding procedures.
Conclusions
Compounded preparations of OAIs can improve pa-
tients’ access to treatment for rare diseases. However,
they should be prepared in accordance to standardized
formulas and compounding procedures and the quality
of the OAI should be demonstrated by a certificate of
analysis according to a specific monograph. In current
study, such standardized formulas and compounding
procedures were developed for seven OAIs to treat pa-
tients with rare diseases when no other treatment is
available. More efforts are needed to develop standard-
ized formulas and compounding procedures for add-
itional OAIs whose clinical efficacy is well-known but
are not available yet to patients due to lack of interest
from the pharmaceutical industry to apply for market
authorization as OMP. Additionally, a legal framework
at EU level is required to enable the potential of
pharmaceutical compounding for OAIs.
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